Clinical trials: Combined Advanced Targeted Therapy
Advanced Metastatic Pancreatic Cancer
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after…
- Trial name
- NCT06662006
- Testing
- nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Melanoma
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1.
- Trial name
- NCT03875079
- Testing
- RO6874281, Pembrolizumab
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations.
- Trial name
- BOREALIS-1 (NCT07021898)
- Testing
- ERAS-4001, ERAS-4001 in combination
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Erasca, Inc.
Rectal Cancer
Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy
feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma collection of response rate (T- and…
- Trial name
- NCT00671645
- Testing
- capecitabine, bevacizumab
- Where
- 10 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Previously Treated, Advanced, Biliary Tract Cancers
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in previously treated advanced unresectable or netastatic biliary tract cancer.
- Trial name
- NCT07635290
- Testing
- Anlotinib + Cadonilimab, PULSAR
- Where
- China
- Volunteers
- 26 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Advanced Unresectable Hepatocellular Carcinoma
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
This clinical study aims to evaluate the efficacy and safety of Retlirafusp alfa Injection (SHR-1701) combined with apatinib in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after…
- Trial name
- NCT07749859
- Testing
- Retlirafusp alfa Injection, apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Clear-cell Metastatic Renal Cell Carcinoma
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell…
- Trial name
- NCT02724020
- Testing
- Everolimus, MLN0128, MLN1117
- Where
- 36 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
First-line Chemotherapy for Recurrent Cervical Cancer
The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Vascular Endothelial Growth Factor 2 Inhibitor
- Trial name
- NCT04188847
- Testing
- Chemotherapy plus apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Lei Li
Head and Neck Squamous Cell Carcinoma
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
This is a prospective, single-arm, phase II study. It aims to evaluate whether neoadjuvant targeted therapy combined with immunotherapy and chemotherapy is effective and safe in patients with locally advanced, resectable head and…
- Trial name
- NCT07906587
- Testing
- Combining nimotuzumab and toripalimab with nab-paclitaxel plus cisplatin
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Exploring the safety and effectiveness of neoadjuvant therapy using benmelstobart combined with anlotinib and chemotherapy for locally advanced squamous cell carcinoma of the head and neck patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
- Trial name
- NCT06699498
- Testing
- Benmelstobart, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thyroid Cancer
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid cancer.
- Trial name
- NCT04521348
- Testing
- multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Fudan University
Advanced Digestive System Tumor
A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors
This is a prospective, open-label, exploratory, phase II basket clinical trial designed to evaluate the efficacy and safety of sintilimab in combination with pyrotinib with or without chemotherapy in patients with advanced…
- Trial name
- CCGLC-018 (NCT07053150)
- Testing
- Sintilimab, Pyrotinib, Optional Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Soft Tissue Sarcoma
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma…
- Trial name
- FIBROSARC (NCT04650984)
- Testing
- Onfekafusp alfa, Doxorubicin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 102 people
- Sponsor
- Philogen S.p.A.
Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib
- Trial name
- ROSE (NCT05811481)
- Testing
- TACE, Regorafenib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- WenBo Guo
Metastatic Breast Cancer, HER2-positive Breast Cancer
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of pyrotinib combination with CDK4/6 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated.
- Trial name
- INPHASE (NCT04095390)
- Testing
- Pyrotinib, SHR6390, Letrozole
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jinming Yu